SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...

A magistrate judge recommends upholding FinCEN’s anti-money laundering rule for real estate, signaling likely win over FNF.

The brokerage industry regulator cited gaps in surveillance, customer due diligence, and red-flag escalation across the ...

The most-read coverage of the latest updates in acute myeloid leukemia (AML) for 2025 focused on the evolution of targeted therapies, the promise of off-the-shelf chimeric antigen receptor (CAR) ...

Overview:  Smarter AI reduces false alerts, reduces fatigue, and helps teams focus on real financial crime rather than noise. Apparent oversight, expl ...

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie recently completed a clinical study titled ...

Panelists discuss how the pathophysiology of acute myeloid leukemia has evolved from a single phenotype understanding to recognizing diverse genetic events that lead to transformation at the ...

The goal of acute myeloid lymphoma (AML) treatment is to put you into remission -- when you have no leukemia cells found in your blood or bone marrow and you have no symptoms of the disease. Most ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

The creation of a single supervisor to oversee AML regulation would effectively transfer this responsibility from the ...